Teva launches personalised digital support for MS patients - PMLiVE
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis - Giancarlo Comi, Yuval Dadon, Nissim Sasson, Joshua R Steinerman, Volker Knappertz, Timothy L Vollmer, Alexey Boyko, Patrick Vermersch, Tjalf
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity | PLOS ONE
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Teva and Active Signs Agreement to Study Laquinimod as Treatment for Neurological Disease
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Teva Relinquishes Laquinimod, Returning the Rights to Active Biotech - Pharmaceutical Processing World
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Teva, Active Biotech Present Positive Findings for RRMS Experimental Therapy Laquinimod
Teva drops development of laquinimod - PharmaTimes
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Laquinimod sodium (ABR-215062 sodium) | Immunomodulator | MedChemExpress
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Linomide - Wikipedia
Letter to investigators involved in the Arpeggio study of Laquinimod …
Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review | SpringerLink
Teva & Active Biotech Press Release: November 4, 2014
Meet the Compound: Laquinimod – HD Insights
